Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| SGMT | 8-K | neutral | 4/10 | Sagimet Biosciences filed an 8-K with an updated investor presentation on October 22, 2026. The presentation highlights | Oct 22, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca announced that the FDA granted accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in adu | Oct 22, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming Group N.V. released preliminary Q3 2026 revenue above market expectations, with total revenues of ~US$117.6M (+ | Oct 22, 2026 |
| KRRO | 8-K | bullish | 6/10 | Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin Deficiency (AATD), s | Oct 22, 2026 |
| UTHR | 8-K | neutral | 4/10 | United Therapeutics announced a $2.0 billion share repurchase authorization, effective through October 21, 2027. The com | Oct 22, 2026 |
| BHVN | 8-K | bullish | 6/10 | Biohaven announced that the FDA accepted for review its resubmitted NDA for troriluzole (Vyglxia) in spinocerebellar ata | Oct 22, 2026 |
| CGTX | 8-K | bullish | 7/10 | Cognition Therapeutics announced FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) in dem | Oct 22, 2026 |
| PULM | 425 | neutral | 4/10 | Eos SENOLYTIX presented positive preclinical survival and healthspan data for PTC-2105 at a conference, and launched a p | Oct 22, 2026 |
| BAK | 6-K | neutral | 3/10 | Braskem filed a Code of Conduct update (routine governance document) and disclosed that NSP Investimentos S.A., em Recup | Oct 21, 2026 |
| SUPN | 8-K | bullish | 6/10 | Supernus announced the FDA recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for advanced P | Oct 21, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron Ltd filed a 6-K announcing that CEO Steven Lydeamore will present at the Emerging Growth Conference on October 2 | Oct 21, 2026 |
| IGC | DEF 14A | neutral | 4/10 | IGC Pharma filed its definitive proxy statement for the 2026 Annual Meeting, seeking shareholder approval for seven prop | Oct 21, 2026 |
| BAK | 6-K | bearish | 7/10 | Creditors holding ~47% ($272M) of Braskem America Finance's $589M in 7.125% Notes due 2041 filed an involuntary Chapter | Oct 21, 2026 |
| RAPP | CLUSTER | bullish | 5/10 | Two insiders at Rapport Therapeutics, including the CFO and a director, made open-market purchases totaling $361K over t | Oct 21, 2026 |
| UTHR | CLUSTER | bearish | 4/10 | CEO Martine Rothblatt exercised options and sold a large block of shares on October 20, 2026, while EVP & General Counse | Oct 21, 2026 |
| ALLO | 144 | neutral | 2/10 | Geoffrey M. Parker, an officer of Allogene Therapeutics, filed a Form 144 notice of intent to sell 100,000 shares of com | Oct 21, 2026 |
| ELOX | 8-K | neutral | 4/10 | Eloxx Pharmaceuticals appointed Geno J. Germano to its board (expanding from five to six directors) and announced the fi | Oct 21, 2026 |
| TKNO | PRESS-RELEASE | neutral | 1/10 | Alpha Teknova, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 21, 2026 |
| ELVN | CLUSTER | neutral | 3/10 | Two senior executives at Enliven Therapeutics (CMO and CFO) sold a combined $424K in open-market sales on October 19, 20 | Oct 21, 2026 |
| LENZ | SC 13G/A | neutral | 4/10 | Millennium Management LLC disclosed a 3.7% passive stake in LENZ Therapeutics as of September 30, 2026, via an amended S | Oct 21, 2026 |
| VNDA | PRESS-RELEASE | neutral | 1/10 | Vanda Pharmaceuticals Inc. announced it will report its Q3 2026 results on October 28, 2026. | Oct 21, 2026 |
| IRON | 424B5 | bearish | 6/10 | Disc Medicine priced a $450M public offering of 6,000,000 shares at $75.00 per share, a 5.6% discount to the prior close | Oct 21, 2026 |
| IRLA | 144 | neutral | 3/10 | Dirk Thye, an officer of IRulya Therapeutics Inc., filed a Form 144 on October 21, 2026, indicating intent to sell 3,700 | Oct 21, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Opportunity Fund I, L.P., a major insider shareholder, filed a Form 144 on October 21, 2026, indicating in | Oct 21, 2026 |
| IRON | 144 | neutral | 3/10 | Atlas Venture Fund X, L.P., a major venture capital shareholder of Disc Medicine (IRON), filed a Form 144 notice of inte | Oct 21, 2026 |
| IRON | 144 | neutral | 2/10 | Atlas Venture Fund XII, L.P., a major venture capital shareholder of Disc Medicine (IRON), filed a Form 144 notice of in | Oct 21, 2026 |
| SXTC | 6-K | bullish | 4/10 | China SXT Pharmaceuticals terminated the over-allotment option from its October 8, 2026 registered direct offering, elim | Oct 21, 2026 |
| HEPA | SC 13G/A | neutral | 3/10 | Kenneth Rickel, a director of Hepion Pharmaceuticals, filed an amended Schedule 13G disclosing beneficial ownership of 7 | Oct 21, 2026 |
| AAPG | 6-K | bullish | 6/10 | Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax (APG-2575) received Breakthrough Therapy Designation (BT | Oct 21, 2026 |
| RZLT | DEF 14A | neutral | 5/10 | Rezolute filed its definitive proxy statement for the 2027 Annual Meeting, seeking shareholder approval for seven direct | Oct 21, 2026 |